ASTRAZENBSEASTRAZENECA PHARMA IND LT· Pharmaceuticals & BiotechnologyHighNegative
Announced Fri, 18 Sept, 2026 · 16:56 IST

AstraZeneca Pharma faces Rs 1.88 lakh ROC penalty for delayed MD filing

Litigation LossRegulatory & Legal View source PDFExplain this filing

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.6%Reaction day
₹6740.00
prior close
₹6700.00
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-1.5% vs market
Pharmaceuticals peers, median of 174sector+0.3%-1.9% vs sector

On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 1.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.0
10m
+0.9
15m
+0.9
30m
+1.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.6-0.1-1.5+0.3-1.9
Next day
-0.3+0.3-0.6+0.1-0.4
2d
-0.3+1.6-1.9+1.1-1.4
3d
-2.1+0.1-2.1-0.0-2.0
4d
-4.3+0.3-4.7+0.2-4.5
5d
-6.9-1.2-5.7-0.5-6.4
1w
-8.2-0.5-7.7-1.0-7.3
15d
-12.4-2.2-10.2-4.5-7.9
1m
-10.0-6.6-3.5-7.2-2.8
2m
—————
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

AstraZeneca Pharma India has been penalised Rs 1.88 lakh by the Registrar of Companies, Bengaluru for delay in filing Form MR-2 related to the 2023 appointment of Dr Sanjeev Kumar Panchal as Managing Director. The Company blamed MCA portal technical glitches that wrongly flagged the DIN as inactive. Officers have each been fined Rs 50,000. Dr Panchal served as MD from January 2023 to June 2025.

Likely market impact

Minor penalty with limited financial impact. A procedural compliance issue disclosed under SEBI rules, unlikely to affect operations or share price.